In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Treatment of severe bleeding under oral anticoagulants - old and new strategies

ACCA webinar

Add to calendar24/03/201618:00 24/03/201619:00 Europe/Paris Treatment of severe bleeding under oral anticoagulants - old and new strategies
Acute Cardiovascular Care Association DD/MM/YYYY
Acute Cardiac Care


Watch the webinar recording


Learning Objectives

  • Effective use of general measures in severe bleeding under vitamin K antagonists
  • General measures to reverse bleeding under NOACs
  • The clinical use of the first available antidote : idarucizumab in dabigatran treated patients/indications and treatment strategy

Get More

Unanswered Questions during the live webinar:

Please find below  the non-answered questions asked during the Webinar and read all the answers from the faculty:

  • When monitoring anticoagulation reversal interventions what haemodynamic & biochemical parameters need to checked?
  • What life-style [e.g. dietary] modifications should be recommended to those started on NOACs (to minimise complications)?
  • I do share the impression of an excessive intended undedosing in many patients. However  this practice seems to have the same bleeding rates. Is there any data published about this fact?
  • Should we use any special NOAC in triple anti-coagulat/platelet therapy in patients after ACS + AF ?
  • US FDA recently approved idaricizumab for dabigatran induced bleeding. In ESC  any recommendation about this new drug ?
  • In terms of safety  what is the better choice of OAC in elderley (>80 y.o..)? 
  • How can i manage patient on either type of anticoagulation planned for elective surgery with high risk of complications if bleeding occur like spinal or cranial surgery ?
  • When we can give again the VKA or NOACs after an attack of bleeding because of it?
  •  If a patient is taking apixaban 2.5 mg twice a day (but should be taking 5 mg twice a day)  and comes to the emergency room with an episode of paroxysmal atrial fibrillation lasting more than 48 hours. Could we perform cardioversion or should we consider that he is not well anticoagulated?
  • In case of thrombolysis what do we do?
  • Can we use NOAC for the treatment of left ventricular thrombus?
  • What about NOAC  before electrophysiological procedures and ablations?
  • Could a patient with Isch. CMP & renal impairment  with INR 1.9 without any anticoagulation  develop an LV thrombus ? & if so .. could this thrombus dissolve spontaneously?
  • Andexenat-antidot for ALL Xa inhibitors?And Ciaraparantag for for all Xa inh or only for edoxaba?
  • How should we monitor NACO?

    Read all the answers here


Professor Harald Darius (speaker)

Professor Peter Clemmensen (speaker)

Professor Kurt Huber (host)

Session information

This webinar is targeted at all professionals involved in the whole management process of patients with CVD specifically cardiologists, emergency specialists, intensivists and paramedics involved in acute cardiac care. During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide feedback live.

The format includes case based presentations, online assessments and live discussions with these key opinion leaders, who will give you some useful tips for your daily clinical practice.

Technical settings

The webinar is available on PC and Tablets. The use of smartphone is not recommended. For the best viewing experience, a high speed Internet connection is required (a minima 2 Mbps).